Blood biomarkers in ischemic stroke: potential role and challenges in clinical practice and research

K Makris, A Haliassos, M Chondrogianni… - Critical reviews in …, 2018 - Taylor & Francis
Fast and accurate diagnosis of stroke is crucial for the immediate application of the right
therapy to patients. However, rapid diagnosis is still a challenge since an ischemic stroke …

The dark side of the force–constraints and complications of cell therapies for stroke

J Boltze, A Arnold, P Walczak, J Jolkkonen… - Frontiers in …, 2015 - frontiersin.org
Cell therapies are increasingly recognized as a promising option to augment the limited
therapeutic arsenal available to fight ischemic stroke. During the last two decades …

Stem cell–based tissue replacement after stroke: factual necessity or notorious fiction?

M Janowski, DC Wagner, J Boltze - Stroke, 2015 - Am Heart Assoc
Janowski et al Stem Cell–Based Stroke Therapies 2355 patient from this trial revealed
neurofilament-immunoreactive neurons at the graft location and the absence of neoplasms …

Evidence implicating blood-brain barrier impairment in the pathogenesis of acquired epilepsy following acute organophosphate intoxication

PN Bernardino, AS Luo, PM Andrew, CM Unkel… - … of Pharmacology and …, 2024 - ASPET
Organophosphate (OP) poisoning can trigger cholinergic crisis, a life-threatening toxidrome
that includes seizures and status epilepticus. These acute toxic responses are associated …

Targeting RNS/caveolin-1/MMP signaling cascades to protect against cerebral ischemia-reperfusion injuries: potential application for drug discovery

H Chen, X Chen, W Li, J Shen - Acta Pharmacologica Sinica, 2018 - nature.com
Reactive nitrogen species (RNS) play important roles in mediating cerebral ischemia-
reperfusion injury. RNS activate multiple signaling pathways and participate in different …

One-compound-multi-target: combination prospect of natural compounds with thrombolytic therapy in acute ischemic stroke

HS Chen, SH Qi, JG Shen - Current Neuropharmacology, 2017 - ingentaconnect.com
Tissue plasminogen activator (t-PA) is the only FDA-approved drug for acute ischemic stroke
treatment, but its clinical use is limited due to the narrow therapeutic time window and …

The exact science of stroke thrombolysis and the quiet art of patient selection

JS Balami, G Hadley, BA Sutherland, H Karbalai… - Brain, 2013 - academic.oup.com
The science of metric-based patient stratification for intravenous thrombolysis, revolutionized
by the landmark National Institute of Neurological Disorders and Stroke trial, has …

Recombinant tissue plasminogen activator induces neurological side effects independent on thrombolysis in mechanical animal models of focal cerebral infarction: a …

MX Dong, QC Hu, P Shen, JX Pan, YD Wei, YY Liu… - PloS one, 2016 - journals.plos.org
Background and Purpose Recombinant tissue plasminogen activator (rtPA) is the only
effective drug approved by US FDA to treat ischemic stroke, and it contains pleiotropic …

Selective inhibition of brain endothelial Rho-kinase-2 provides optimal protection of an in vitro blood-brain barrier from tissue-type plasminogen activator and plasmin

B Niego, N Lee, P Larsson, TM De Silva, AEL Au… - PLoS …, 2017 - journals.plos.org
Rho-kinase (ROCK) inhibition, broadly utilised in cardiovascular disease, may protect the
blood-brain barrier (BBB) during thrombolysis from rt-PA-induced damage. While the use of …

Pharmacological therapy of acute ischaemic stroke: achievements and problems

A Moretti, F Ferrari, RF Villa - Pharmacology & therapeutics, 2015 - Elsevier
Acute ischaemic stroke (AIS) is a leading cause of death and disability worldwide. Its
incidence and prevalence increase considerably with age and numbers will grow with an …